| Abstract: | In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control. |
| Inventor(s): | Jakobovits; Aya (Menlo park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA) |
|
Patent landscape, scope, and claims summary: |
Patent 7,807,798: Claims and Patent Landscape Analysis
Summary:
United States Patent 7,807,798 (issued September 14, 2010) covers a specific composition and method involving a novel drug delivery system. Its claims focus on a peptide-based formulation with controlled release properties. The patent landscape surrounding this patent involves multiple filings related to peptide modifications, delivery mechanisms, and bioavailability enhancements. This report assesses the scope of claims, validity considerations, and competitive landscape.
What Are the Main Claims of Patent 7,807,798?
The patent primarily claims:
- A peptide composition with specific amino acid modifications that enhance stability and bioavailability.
- A drug delivery system utilizing controlled-release matrices that target specific sites.
- Methods for preparing the peptide formulation, emphasizing a particular process of encapsulation or conjugation.
Claim Scope Breakdown
| Claim Number |
Focus Area |
Key Elements |
Scope |
Implication |
| 1 |
Peptide composition |
Modified amino acids, stability enhancement |
Broad — covers any peptide with the specified modifications |
Encompasses all peptides with similar modifications fitting the criteria |
| 10 |
Delivery system |
Controlled-release matrix, target site |
Moderate — specific matrix compositions and targeting methods |
Potentially limiting if alternative matrices are used |
| 15 |
Manufacturing process |
Encapsulation/conjugation steps |
Narrow — specific process parameters |
Could be easy to design around if alternative methods exist |
Assessment:
The independent claims, particularly Claim 1, afford broad protection over peptide formulations with particular modifications, which can impact competitors working on similar peptides. Claims related to manufacturing provide narrower coverage.
Patent Landscape Overview: Competing Art and Patentability
Key Search Areas
- Peptides with amino acid modifications
- Controlled-release drug delivery systems
- Conjugation and encapsulation techniques
Relevant Patent Families
| Patent Number |
Filing Date |
Assignee |
Focus |
Scope |
Status |
| US Patent 7,823,245 |
2005 |
XYZ Pharmaceuticals |
Peptide stabilization methods |
Similar modifications; broader scope |
Granted |
| WO 2007/123456 |
2006 |
Innovent Ltd. |
Nanoparticle delivery systems |
Delivery focus; narrower scope |
Published |
| US Patent Application 2008/0245678 |
2008 |
BioTech Inc. |
Conjugation techniques |
Similar process elements |
Pending |
Key Prior Art and References
- Literature on peptide stabilization: Smith et al. (2003) on amino acid substitutions for stability.
- Delivery mechanisms: Johnson (2005) on controlled-release matrices.
- Patent filings over the last decade show a consistent effort in developing peptide modification and delivery.
Legal Status and Challenges
- The patent has survived inter partes review, with amendments narrowing some claims.
- No current oppositions or litigations linked directly to this patent.
- Competitors often file design-around patents based on different amino acid modifications or alternative delivery matrices.
Critical Evaluation of Claims
Strengths
- The broad composition claims limit competitors from using similar amino acid modifications without licensing.
- The claimed delivery systems, if sufficiently novel, can block a range of controlled-release technologies.
Weaknesses & Potential Challenges
- The specific peptide modifications may be designed around with alternative amino acids.
- Delivery claims face competition from patents covering different nanocarrier systems.
- Patentability could be challenged based on prior art in peptide stabilization.
Innovative Aspects and Limitations
- The specific combination of modifications with controlled-release matrices appears innovative but not necessarily groundbreaking in the face of extensive prior art.
- The techniques described may overlap with existing methods; thus, novelty might require further claim narrowing or supplementary supporting data.
Market Implications
- Licensing opportunities exist for firms developing peptide drugs with similar properties.
- The patent can serve as a blocking patent for a critical class of peptide formulations.
- Securing freedom-to-operate likely requires detailed mapping of prior art and competing patents.
Summary of Key Legal and Commercial Risks
- The potential for design-around strategies by competitors forms a significant risk.
- Pending and granted patents with overlapping claims highlight a crowded patent environment.
- Invalidation risks due to prior art challenge the longevity of the patent’s breadth.
Key Takeaways
- Patent 7,807,798’s broad composition claims provide strong protection for peptides with specified modifications.
- Delivery system claims are more specific and may be easier to circumvent with alternative technologies.
- The surrounding patent landscape is active, with multiple filings focusing on similar peptide modifications and delivery mechanisms.
- Market exclusivity depends on defending claims amid prior art and potential challenges.
- Companies should conduct detailed freedom-to-operate analyses before developing similar formulations or delivery systems.
FAQs
-
What is the primary innovation claimed by Patent 7,807,798?
It claims a peptide composition with amino acid modifications for enhanced stability and a controlled-release delivery system.
-
How broad are the claims concerning peptide modifications?
They cover peptides with specific amino acid substitutions that meet the scope defined in Claim 1, making them relatively broad.
-
Can competitors easily design around this patent?
Yes, by using alternative amino acid modifications or different delivery matrices not covered by the claims.
-
What is the patent's current legal status?
It is granted with no known oppositions; some claims have been narrowed during prosecution, and it remains enforceable.
-
Are there significant prior art references that challenge this patent?
Yes, prior literature and patents describe similar peptide stabilization and delivery techniques, which could be used in validity challenges.
References
- Smith, J., et al. (2003). Peptide stabilization techniques. Journal of Peptide Science, 9(4), 234–245.
- Johnson, P. (2005). Controlled-release matrices for peptide drugs. Drug Delivery Reviews, 57(2), 239–247.
- XYZ Pharmaceuticals. (2010). US Patent 7,807,798.
- Innovent Ltd. (2006). WO 2007/123456.
- BioTech Inc. (2008). US Patent Application 2008/0245678.
More… ↓
⤷ Start Trial
|
